Submitted:
04 March 2024
Posted:
04 March 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Case Selection
2.2. Etiology of AKI
2.3. Therapeutical Management and Outcome
2.4. Hematological and Biochemical Parameters at Hospital Admission
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Conflicts of Interest
References
- Rimer, D.; Chen, H.; Bar-Nathan, M.; Segev, G. Acute kidney injury in dogs: Etiology, clinical and clinicopathologic findings, prognostic markers, and outcome. J Vet Intern Med. 2022, 36, 609–618. [Google Scholar] [CrossRef]
- Legatti, S.A.M.; El Dib, R.; Legatti, E.; Botan, A.G.; Camargo, S.E.A.; Agarwal, A.; Barretti, P.; Paes, A.C. Acute kidney injury in cats and dogs: A proportional meta-analysis of case series studies. PLoS One. 2018, 13, e0190772. [Google Scholar] [CrossRef]
- Hales, M.; Solez, K.; Kjellstrand, C. The anemia of acute renal failure: association with oliguria and elevated blood urea. Ren Fail. 1994, 16, 125–131. [Google Scholar] [CrossRef]
- Powell-Tuck, J.; Crichton, S.; Raimundo, M.; Camporota, L.; Wyncoll, D.; Ostermann, M. Anaemia is not a risk factor for progression of acute kidney injury: a retrospective analysis. Crit Care. 2016, 2, 52. [Google Scholar] [CrossRef]
- Nishimoto, M.; Murashima, M.; Kokubu, M.; Matsui, M.; Eriguchi, M.; Samejima, K.I.; Akai, Y.; Tsuruya, K. Anemia following acute kidney injury after noncardiac surgery and long-term outcomes: the NARA-AKI cohort study. Clin Kidney J. 2020, 14, 673–680. [Google Scholar] [CrossRef] [PubMed]
- Haase, M.; Bellomo, R.; Story, D.; Letis, A.; Klemz, K.; Matalanis, G.; Seevanayagam, S.; Dragun, D.; Seeliger, E.; Mertens, P.R.; Haase-Fielitz, A. Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. Nephrol Dial Transplant. 2012, 27, 153–160. [Google Scholar] [CrossRef] [PubMed]
- Karkouti, K.; Beattie, W.S.; Wijeysundera, D.N.; Rao, V.; Chan, C.; Dattilo, K.M.; Djaiani, G.; Ivanov, J.; Karski, J.; David, T.E. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg. 2005, 129, 391–400. [Google Scholar] [CrossRef] [PubMed]
- Woo, S.H.; Zavodnick, J.; Ackermann, L.; Maarouf, O.H.; Zhang, J.; Cowan, S.W. Development and Validation of a Web-Based Prediction Model for AKI after Surgery. Kidney360. 2020, 2, 215–223. [Google Scholar] [CrossRef] [PubMed]
- King, L.G.; Giger, U.; Diserens, D.; Nagode, L.A. Anemia of chronic renal failure in dogs. J Vet Intern Med. 1992, 6, 264–270. [Google Scholar] [CrossRef] [PubMed]
- Lippi, I.; Perondi, F.; Lubas, G.; Gori, E.; Pierini, A.; D'Addetta, A.; Marchetti, V. Erythrogram Patterns in Dogs with Chronic Kidney Disease. Vet Sci. 2021, 8, 123. [Google Scholar] [CrossRef] [PubMed]
- Available online: http://www.iris-kidney.com.
- Bragato, N.; Borges, N.C.; Soares Fioravanti, M.C. B-mode and Doppler ultrasound of chronic kidney disease in dogs and cats. Vet. Res. Commun. 2017, 41, 307–315. [Google Scholar] [CrossRef]
- Ross, L. Acute Kidney Injury in Dogs and Cats. Vet Clin North Am Small Anim Pract. 2022, 52, 659–672. [Google Scholar] [CrossRef] [PubMed]
- Tvedten, H. Laboratory and clinical diagnosis of anemia. In Schalm’s Veterinary Hematology, 6th ed.; Weiss, D.J., Wardrop, K.J., Eds.; Wiley-Blackwell: Ames, IA, USA, 2010; pp. 152–161. [Google Scholar]
- Aoun, M.; Sleilaty, G.; Boueri, C.; Younes, E.; Gabriel, K.; Kahwaji, R.M.; Hilal, N.; Hawi, J.; Araman, R.; Chelala, D.; Beaini, C. Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial. BMC Nephrol. 2022, 23, 100. [Google Scholar] [CrossRef] [PubMed]
- Kwaan, H.C. Infection and anemia. Infect Disord Drug Targets. 2011, 11, 40–44. [Google Scholar] [CrossRef] [PubMed]
- Nairz, M.; Weiss, G. Iron in infection and immunity. Mol Aspects Med. 2020, 75, 100864. [Google Scholar] [CrossRef] [PubMed]
- Honse, C.O.; Figueiredo, F.B.; de Alencar, N.X.; Madeira Mde, F.; Gremião, I.D.; Schubach, T.M. Disseminated intravascular coagulation in a dog naturally infected by Leishmania (Leishmania) chagasi from Rio de Janeiro - Brazil. BMC Vet Res. 2013, 9, 43. [Google Scholar] [CrossRef] [PubMed]
- Rafaj, R.B.; Matijatko, V.; Kis, I.; Kucer, N.; Zivicnjak, T.; Lemo, N.; Zvorc, Z.; Brkljacić, M.; Mrljak, V. Alterations in some blood coagulation parameters in naturally occurring cases of canine babesiosis. Acta Vet Hung. 2009, 57, 295–304. [Google Scholar] [CrossRef] [PubMed]
- Sonderegger, F.; Nentwig, A.; Schweighauser, A.; Francey, T.; Marti, E.; Mirkovitch, J.; Schuller, S. Association of markers of endothelial activation and dysfunction with occurrence and outcome of pulmonary hemorrhage in dogs with leptospirosis. J Vet Intern Med. 2021, 35, 1789–1799. [Google Scholar] [CrossRef]
- Yamashita, T.; Noiri, E.; Hamasaki, Y.; Matsubara, T.; Ishii, T.; Yahagi, N.; Nangaku, M.; Doi, K. Erythropoietin concentration in acute kidney injury is associated with insulin-like growth factor-binding protein-1. Nephrology (Carlton). 2016, 21, 693–699. [Google Scholar] [CrossRef]
- Park, J.; Gage, B.F.; Vijayan, A. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis. 2005, 46, 791–798. [Google Scholar] [CrossRef]
- Wu, C.J.; Chen, C.Y.; Lai,T. S.; Wu, P.C.; Chuang, C.K.; Sun, F.J.; Liu, H.L.; Chen, H.H.; Yeh, H.I.; Lin, C.S.; Lin,C.J. The role of indoxyl sulfate in renal anemia in patients with chronic kidney disease. Oncotarget. 2017, 8, 83030–83037. [Google Scholar] [CrossRef] [PubMed]
- Hayden, S.J. , Albert, T.J.; Watkins, T.R.; Swenson, E.R. Anemia in critical illness: insights into etiology, consequences, and management. Am J Respir Crit Care Med. 2012, 185, 1049–1057. [Google Scholar] [CrossRef]
- Han, S.S.; Baek, S.H.; Ahn, S.Y.; Chin, H.J.; Na, K.Y.; Chae, D.W.; Kim, S. Anemia Is a Risk Factor for Acute Kidney Injury and Long-Term Mortality in Critically Ill Patients. Tohoku J Exp Med. 2015, 237, 287–295. [Google Scholar] [CrossRef] [PubMed]
| AKI Grade (a) |
AKI (n=121) |
AKI 2 (n=10) |
AKI 3 (n=22) |
AKI 4 (n=48) |
AKI 5 (n=40) |
RR | p-Value |
|---|---|---|---|---|---|---|---|
|
RBC (M/μL) |
3.9 (1.5-9.4) | 6.3 (1.5-9.1) | 5.3 (2.3-9.4) | 4.7 (1.6-8.7) | 5.0 (1.8-8.3) | 5.6-8.8 | 0.486 |
|
HCT (%) |
31.8 + 10.3 | 38.8 + 15.3 | 33.0 + 10.3 | 29.7 + 8.7 | 32.0 + 10.0 | 37.3-61.7 | 0.140 |
|
HGB (g/dL) |
11.5 + 3.7 | 13.0 + 5.2 | 11.8 + 3.8 | 10.9 + 3.4 | 11.7 + 3.6 | 13.1-20.5 | 0.540 |
|
MCV (fL) |
63.2 (6.8-84.4) | 64.5 (51.3-73.0) | 63.4 (54.3-68.5) | 63.0 (6.8-84.4) | 63.3 (51.1-72.0) | 61.6-73.5 | 0.975 |
|
MCH (pg) |
23.1 (2.0-26.3) | 21.2 (18.4-25.1) | 22.9 (2.0-24.5) | 23.2 (18.2-26.3) | 23.2 (17.6-25.5) | 21.2-25.9 | 0.155 |
|
MCHC (g/dL) |
36.4 (15.6-40.9)* | 33.8 (15.6-37.0)** | 35.8 (31.9-39.9)* | 37.0 (31.2-39.6)* | 37.0 (33.8-40.9)* | 32.0-37.9 | 0.001 |
|
RDW (%) |
15.6 (0.4-32.2) | 17.0 (0.4-25.5) | 16.1 (13.8-32.2) | 15.5 (12.2-32.2) | 15.3 (12.7-26.7) | 13.6-21.7 | 0.291 |
|
%RET (%) |
0.4 (0.1-18.7) | 0.7 (0.3-15.4) | 0.3 (0.1-2.5) | 0.6 (0.1-11.2) | 0.3 (0.1-18.7) | 0-10 | 0.077 |
|
RET (K/μL) |
17.4 (3.2-236.8) | 40.7 (15.4-97.7) | 13.4 (7.7-97.7) | 22.1 (3.8-236.8) | 13.7 (3.2-60.7) | 10-110 | 0.05 |
|
Cr (mg/dL) |
8.3 (1.7-26.6) | 2.1 (1.7-2.5)* | 3.7 (2.6-5.0)* | 8.0 (5.1-10.0)** | 12.6 (10.6-26.6)*** | 0.6-1.5 | <0.0001 |
|
Urea (mg/dL) |
303.1 + 134.9 | 116.2 + 41.5* | 204.1 + 90.6* | 308.6 + 100.7** | 397.9 + 121.4*** | 15-55 | <0.0001 |
|
TCa (mg/dL) |
10.1 + 2.5 | 9.5 + 0.8 | 9.9 + 2.2 | 10.3 + 3.1 | 10.0 + 2.1 | 8.7-11.8 | 0.927 |
|
P (mg/dL) |
13.2 + 5.1* | 6.6 + 2.8** | 9.0 + 3.6** | 13.4 + 4.4* | 15.9 + 4.5*** | 2.5-5.0 | <0.0001 |
|
Na+ (mEq/L) |
147 (117-172) | 156 (140-166) | 149 (117-161) | 145 (123-171) | 148 (122-172) | 117-172 | 0.176 |
|
K+ (mEq/L) |
5.0 (2.5-11.0) | 4.4 (3.8-8.8) | 4.5 (2.5-7.3) | 5.6 (2.7-9.0) | 5.1 (3.4-11.0) | 3.6-4.8 | 0.230 |
|
Etiology (b) |
IS | INF | NEP | OBS | UK | p-value | |
|
RBC (M/μL) |
5.0 (1.9-9.1) | 4.6 (1.6-7.3) | 5.9 (3.4-8.7) | 3.8 (1.5-8.1) | 5.0 (1.8-9.4) | 0.05 | |
|
HCT (%) |
31.3 + 11.4 | 28.5 + 7.9* | 39.0 + 10.8** | 26.8 + 16.8 | 32.9 + 9.6 | 0.01 | |
|
HGB (g/dL) |
11.4 + 4.2 | 10.4 + 2.9* | 13.7 + 3.9** | 9.1 + 5.4 | 12.0 + 3.6 | 0.02 | |
|
MCV (fL) |
62.0 (56.2-75.5) | 61.5 (6.8-84.4)* | 65.0 (62.1-73.3)** | 65.3 (51.3-71.5) | 63.3 (51.1-73.0) | 0.02 | |
|
MCH (pg) |
23.1 (19.9-25.0) | 22.8 (2.0-26.3) | 23.4 (19.0-25.3) | 22.2 (18.4-25.1) | 23.2 (17.6-25.5) | 0.567 | |
|
MCHC (g/dL) |
36.4 (33.1-38.3) | 36.7 (31.2-40.9) | 35.9 (27.8-38.1) | 34.1 (15.6-35.8) | 36.9 (31.9-39.4) | 0.05 | |
|
RDW (%) |
15.8 (13.8-30.0) | 15.9 (13.5-32.2) | 15.1 (12.2-19.6) | 16.9 (0.4-18.3) | 15.4 (12.7-26.7) | 0.486 | |
|
%RET (%) |
0.4 (0.1-10.4) | 0.6 (0.1-11.2)* | 0.2 (0.1-0.7)** | 5.7 (0.4-15.4)* | 0.4 (0.1-18.7) | 0.006 | |
|
RET (K/μL) |
23.6 (5.5-200.3) | 19.6 (4.4-185.5) | 13.3 (3.5-44.2) | 25.1 (15.4-236.8) | 17.4 (3.2-97.7) | 0.393 | |
|
Cr (mg/dL) |
8.1 (2.0-12.8) | 6.8 (2.3-17.0)* | 7.0 (1.7-26.6) | 2.5 (1.7-8.4)* | 10.2 (1.9-25.6)** | 0.002 | |
|
Urea (mg/dL) |
319.4 + 117.5 | 297.4 + 139.7 | 262.6 + 192.2 | 166.6 + 98.3 | 327.8 + 112.1 | 0.07 | |
|
TCa (mg/dL) |
9.3 + 1.8 | 10.7 + 2.4 | 9.8 + 2.1 | 9.3 + 1.2 | 10.3 + 2.4 | 0.380 | |
|
P (mg/dL) |
13.4 + 4.0 | 12.9 + 5.1 | 10.6 + 6.2 | 7.9 + 3.7 | 14.5 + 4.6 | 0.03 | |
|
Na+ (mEq/L) |
145.5 (136.0-160.0) | 145.0 (122.0-159.0) | 145.6 (134.0-166.0) | 144.0 (139.0-148.0) | 149.0 (117.0-172.0) | 0.417 | |
|
K+ (mEq/L) |
4.6 (3.3-8.8) | 4.9 (2.7-9.0) | 4.7 (3.4-11.0) | 4.8 (3.8-6.1) | 5.5 (2.5-8.4) | 0.319 | |
|
Therapeutical management (c) |
Medical |
Hemodialysis |
p-value | ||||
|
RBC (M/μL) |
5.3 (1.5-9.4) | 4.8 (1.8-8.7) | 0.464 | ||||
|
HCT (%) |
33.0 + 11.7 | 31.0 + 9.1 | 0.285 | ||||
|
HGB (g/dL) |
11.9 + 4.4 | 11.3 + 3.2 | 0.374 | ||||
|
MCV (fL) |
32.6 (8.1-58.2) | 30.3 (10.7-55.7) | 0.321 | ||||
|
MCH (pg) |
23.2 (17.6-26.3) | 23.1 (2.0-25.8) | 0.358 | ||||
|
MCHC (g/dL) |
36.1 (15.6-39.1) | 36.7 (27.8-40.9) | 0.09 | ||||
|
RDW (%) |
15.6 (0.4-32.2) | 15.6 (12.2-26.0) | 0.737 | ||||
|
%RET (%) |
0.5 (0.1-15.4) | 0.4 (0.1-18.7) | 0.572 | ||||
|
RET (K/μL) |
17.4 (3.8-200.3) | 17.4 (3.2-236.8) | 0.416 | ||||
|
Cr (mg/dL) |
6.2 (1.7-20.6) | 9.0 (1.7-26.6) | 0.01 | ||||
|
Urea (mg/dL) |
273.7 + 132.3 | 324.1 + 133.7 | 0.04 | ||||
|
TCa (mg/dL) |
10.0 + 2.1 | 10.3 + 2.4 | 0.498 | ||||
|
P (mg/dL) |
12.6 + 5.2 | 13.6 + 4.9 | 0.340 | ||||
|
Na+ (mEq/L) |
149.0 (117.0-172.0) | 145.2 (122.0-166.0) | 0.07 | ||||
|
K+ (mEq/L) |
5.3 (2.5-8.8) | 4.9 (3.2-11.0) | 0.401 | ||||
|
Outcome (d) |
Survivors | Non-survivors | p-value | ||||
|
RBC (M/μL) |
4.8 (1.5-8.7) | 4.9 (1.6-9.4) | 0.612 | ||||
|
HCT (%) |
32.1 + 9.5 | 31.4 + 11.2 | 0.695 | ||||
|
HGB (g/dL) |
11.5 + 3.3 | 11.5 + 4.2 | 0.982 | ||||
|
MCV (fL) |
63.0 (6.8-73.0) | 63.6 (56.0-84.4) | 0.335 | ||||
|
MCH (pg) |
23.0 (2.0-25.4) | 23.2 (19.9-26.3) | 0.01 | ||||
|
MCHC (g/dL) |
36.2 (15.6-39.6) | 37.0 (31.2-40.9) | 0.111 | ||||
|
RDW (%) |
15.7 (0.4-26.7) | 15.3 (12.2-32.2) | 0.242 | ||||
|
%RET (%) |
0.4 (0.1-18.7) | 0.5 (0.1-11.2) | 0.703 | ||||
|
RET (K/μL) |
17.3 (3.5-236.8) | 17.4 (3.2-200.3) | 0.687 | ||||
|
Cr (mg/dL) |
7.2 (1.7-22.6) | 9.5 (2.0-26.6) | 0.02 | ||||
|
Urea (mg/dL) |
279.7 + 125.6 | 331.8 + 141.3 | 0.03 | ||||
|
TCa (mg/dL) |
10.7 + 2.3 | 9.6 + 2.2 | 0.01 | ||||
|
P (mg/dL) |
11.5 + 4.5 | 15.2 + 5.0 | 0.0002 | ||||
|
Na+ (mEq/L) |
149.0 (134.0-172.0) | 144.0 (117.0-171.0) | 0.03 | ||||
|
K+ (mEq/L) |
4.9 (3.3-9.0) | 5.1 (2.5-11.0) | 0.420 | ||||
| Variables |
Anemia (%) |
Severity (%) | Degree of regeneration (%) | ||||
|---|---|---|---|---|---|---|---|
|
Yes |
No |
Mild to moderate | Severe to very severe | None | Mild | Moderate | |
|
AKI grade AKI 2 AKI 3 AKI 4 AKI 5 |
40% 64% 83% 70% p<0.0001 |
60% 36% 17% 30% |
75% 86% 83% 85% p=0.163 |
25% 14% 17% 15% |
100% 85% 86% 100% p<0.0001 |
- 15% 7% - |
- - 7% - |
|
Etiology Ischemic/Inflammatory Infectious Nephrotoxic Obstructive Unknown |
82% 81% 43% 80% 70% p<0.0001 |
18% 19% 57% 20% 30% |
72% 80% 100% 50% 94% p<0.0001 |
28% 20% - 50% 6% |
79% 94% 100% 75% 94% p<0.0001 |
14% 3% - - 6% |
7% 3% - 25% - |
|
Therapeutical approach Medical management Hemodialysis |
64% 77% p=0.04 |
36% 23% |
84% 83% p=0.848 |
16% 17% |
88% 91% p=0.141 |
6% 8% |
6% 1% |
|
Outcome Survived Deceased |
74% 64% p=0.433 |
23% 36% |
92% 73% p=0.0004 |
8% 27% |
88% 92% p=0.07 |
10% 3% |
2% 5% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
